Resistance to Immunotherapeutic Antibodies in Cancer: Strategies to Overcome Resistance: Resistance to Targeted Anti-Cancer Therapeutics, cartea 2
Editat de Benjamin Bonavidaen Limba Engleză Hardback – 5 aug 2013
Toate formatele și edițiile | Preț | Express |
---|---|---|
Paperback (1) | 1090.04 lei 6-8 săpt. | |
Springer – 22 aug 2015 | 1090.04 lei 6-8 săpt. | |
Hardback (1) | 1093.88 lei 6-8 săpt. | |
Springer – 5 aug 2013 | 1093.88 lei 6-8 săpt. |
Din seria Resistance to Targeted Anti-Cancer Therapeutics
- 5% Preț: 718.10 lei
- 5% Preț: 1107.21 lei
- 5% Preț: 1096.10 lei
- 5% Preț: 1100.30 lei
- 5% Preț: 1093.35 lei
- 5% Preț: 1103.22 lei
- 5% Preț: 1093.88 lei
- 5% Preț: 1099.35 lei
- 5% Preț: 1096.10 lei
- 5% Preț: 841.00 lei
- 5% Preț: 715.91 lei
- 5% Preț: 714.83 lei
- 5% Preț: 712.25 lei
- 5% Preț: 1024.59 lei
- 5% Preț: 723.57 lei
- 5% Preț: 721.19 lei
- 5% Preț: 721.19 lei
- 5% Preț: 726.68 lei
- 5% Preț: 723.21 lei
- 5% Preț: 717.73 lei
Preț: 1093.88 lei
Preț vechi: 1151.45 lei
-5% Nou
Puncte Express: 1641
Preț estimativ în valută:
209.35€ • 216.90$ • 174.71£
209.35€ • 216.90$ • 174.71£
Carte tipărită la comandă
Livrare economică 22 martie-05 aprilie
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9781461476535
ISBN-10: 1461476534
Pagini: 255
Ilustrații: XIII, 202 p.
Dimensiuni: 155 x 235 x 17 mm
Greutate: 0.41 kg
Ediția:2013
Editura: Springer
Colecția Springer
Seria Resistance to Targeted Anti-Cancer Therapeutics
Locul publicării:New York, NY, United States
ISBN-10: 1461476534
Pagini: 255
Ilustrații: XIII, 202 p.
Dimensiuni: 155 x 235 x 17 mm
Greutate: 0.41 kg
Ediția:2013
Editura: Springer
Colecția Springer
Seria Resistance to Targeted Anti-Cancer Therapeutics
Locul publicării:New York, NY, United States
Public țintă
ResearchCuprins
Preface.- Introduction and generation of chimeric and humanized mAbs.- mAbs targeted against cancer cells and antibodies targeted against the tumor microenvironment.- Antibodies directed against different major cancers: Effects when used alone or in combination with drugs.- Mechanisms of antibodies-mediated responses, in vitro and in vivo.- Molecular Pathways.- Molecular Signatures.- Identification of resistance targets for intervention.- Various chemicals that can sensitize resistant tumor cells.- Other mAbs.- Proteasome inhibitors.- Divalent mAbs.- Antibodies coupled to chemical inhibitors.- Antibodies coupled to cytokines.- Nanoparticles with mAbs.- Index.
Notă biografică
Dr. Benjamin Bonavida is a professor at UCLA's David Geffen School of Medicine for the Department of Microbiology, Immunology, & Molecular Genetics. His other appointments include being a member of the Department of Defense Congressionally Directed Medical Research Program, Member of the National Cancer Institute's SPORE Program, member of the International Scientific Advisory Board of the Israel Cancer Research Foundation, to name a few. He's currently a scientific reviewer for several journals and a member of editorial boards including Journal of Clinical Immunology, International Journal of Oncology, and Cancer Biotherapy & Radiopharmaceuticals. In his career, he's published over 450 papers and reviews, and he's also edited two books with Springer in the past. For more information, please see the CV attached herewith.
Textul de pe ultima copertă
The current application of antibody-meditated targeted therapy against cancer has resulted in significant objective clinical responses, prolongation of survival and even cures. More than 20 mAbs have been approved for human use targeting a range of different cancers. However, a major drawback of mAb therapeutics is that a subset of patients does not initially respond and another initially responding subset develops resistance to further treatments. At the present time, there are no effective therapies for these subsets of cancer patients. The analyses of underlying mechanisms responsible for resistance are necessary to develop and generate new targeted therapies that overcome the resistance.
Resistance to Immunotherapeutic Antibodies in Cancer: Strategies to Overcome Resistance is a timely volume that deals with various mechanisms of resistance to anti-cancer mAbs therapeutics as well as it deals with novel approaches to overcome resistance. The reviews in this volume are written by highly qualified, established and experienced leaders in the field of resistance to anti-cancer mAbs.
Resistance to Immunotherapeutic Antibodies in Cancer: Strategies to Overcome Resistance is a timely volume that deals with various mechanisms of resistance to anti-cancer mAbs therapeutics as well as it deals with novel approaches to overcome resistance. The reviews in this volume are written by highly qualified, established and experienced leaders in the field of resistance to anti-cancer mAbs.
Caracteristici
Summarizes common and unique features of mAbs against various cancers Explores the latest developments on the molecular, biochemical and genetic mechanisms of resistance by various mAbs Covers the potential use of the combination treatment of mAbs with other drugs/mAbs to reverse resistance Includes supplementary material: sn.pub/extras